A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.
Important Disclaimer This article is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment recommendation. Cannabis-based products for medicinal use (CBPMs) are prescription-only medicines in the UK and can only be prescribed by specialist doctors on the GMC Specialist Register. Always consult a qualified healthcare professional before considering any treatment. Laws, guidelines, and evidence evolve; check official sources (GMC, NICE, MHRA, Home Office) for the latest. Use of this site is at your own risk.
Anxiety disorders are among the most common mental health conditions in the UK, affecting around 1 in 6 adults at any time. Generalised anxiety disorder (GAD), panic disorder, social anxiety, PTSD, and related issues can severely impact daily life. While traditional treatments like CBT, SSRIs/SNRIs, and lifestyle changes help many people, some find limited relief or experience side effects.
In 2025, private specialist clinics prescribe CBPMs to patients with anxiety where other options have been insufficient. This guide covers current evidence, access routes, CBD vs THC considerations, and key risks.
1. Evidence for Medical Cannabis in Anxiety (2025 Update)
Evidence remains mixed but growing, mostly from real-world patient registries rather than large RCTs (randomised controlled trials).
- Real-World UK Data UK Medical Cannabis Registry (Curaleaf Clinic/Sapphire) and T21 registry show significant anxiety improvements (measured by GAD-7 scale) at 1, 3, and 6 months for patients prescribed CBPMs. Many report reduced symptoms, better sleep, and improved quality of life. Anxiety is the second most common indication (after chronic pain), with ~30–40% of private patients seeking help for anxiety/PTSD/depression.
- CBD-Focused Studies CBD (cannabidiol) shows promise for anxiety reduction, particularly at moderate doses (300 mg+ in some trials). It may act on serotonin receptors (5-HT1A) and enhance natural endocannabinoids like anandamide. CBD-dominant products often have fewer risks than THC.
- THC and Balanced Products THC (tetrahydrocannabinol) is dose-dependent: low doses may reduce anxiety in some, but higher doses can increase it (e.g., paranoia, racing thoughts). Balanced THC/CBD products are common in UK private practice and may balance effects.
- NHS Position NICE and NHS England do not recommend CBPMs for anxiety due to limited high-quality evidence. NHS access is extremely rare (handful of cases nationwide). Private clinics have more flexibility based on real-world data and specialist judgement.
- Limitations Most evidence is observational (not placebo-controlled RCTs). Long-term safety, optimal dosing, and THC/CBD ratios need more research. Some patients report no benefit or worsening symptoms.
2. Who Can Access Medical Cannabis for Anxiety in the UK 2025?
NHS: Virtually impossible for anxiety alone (not NICE-approved).
Private Clinics: Realistic path for eligible patients. Eligibility criteria (private):
- Diagnosed anxiety disorder (e.g., GAD, PTSD, social anxiety)
- At least 2 conventional treatments tried (e.g., CBT, SSRIs, counselling) with insufficient benefit or intolerable side effects
- Medical records showing history
Common Clinics (2025 examples):
- Releaf, Alternaleaf, Curaleaf Clinic, Mamedica, Lyphe, Zerenia
- Process: Online eligibility check → upload records → specialist consultation (£50–£200) → prescription if suitable → medication from licensed pharmacy (oils, capsules, flower).
Costs
- Initial consultation: £50–£200
- Medication: £50–£400+/month (CBD-dominant cheaper; THC-inclusive higher)
- Follow-ups: £65–£150 every 1–3 months
3. CBD vs THC for Anxiety – What UK Patients Get
| Aspect | CBD-Dominant Products | THC-Inclusive Products |
|---|---|---|
| Typical Effects | Calming, non-psychoactive, may reduce anxiety | Dose-dependent: low dose calming; high dose potentially anxiety-increasing |
| Common Forms | Oils, capsules, broad-spectrum (0% THC) | Balanced THC/CBD oils, flower (vaporised) |
| Evidence for Anxiety | Stronger for CBD alone (serotonin modulation) | Mixed; some real-world benefit in balanced forms |
| Risks | Generally lower (dry mouth, fatigue rare) | Higher (paranoia, dependence, cognitive effects) |
| UK Availability | Widely private-prescribed | Private only; strict monitoring |
Private clinics often start with CBD-dominant/low-THC, titrating up based on response.
4. Risks and Side Effects
- Common: Dry mouth, fatigue, dizziness, appetite changes
- THC-related: Increased anxiety/paranoia (high doses), dependence, impaired cognition, driving risks (DVLA strict rules)
- General: Interactions with other meds (e.g., antidepressants), psychiatric effects in vulnerable people
- Long-term: Limited data; potential for tolerance or worsening symptoms in some
Private specialists monitor closely and start low/slow.
5. Legal & Practical Notes
- CBPMs are prescription-only (Schedule 2).
- Possession without prescription illegal (Class B).
- Driving: Impairment windows apply — check DVLA.
- No NHS funding for anxiety — full private cost.
Sources
- UK Medical Cannabis Registry (Curaleaf/Sapphire) outcomes
- NICE guidelines on CBPMs
- GMC specialist prescribing rules
- Real-world studies on GAD and CBMPs (2023–2025)
- Clinic data (Releaf, Alternaleaf, Curaleaf)